Listar Enfermedades Desmielinizantes.pósters por autor "Comi, Giancarlo"

Mostrando ítems 1-2 de 2

Baseline Characteristics of Patients with Relapsing Multiple Sclerosis in ASCLEPIOS Phase 3 Trials of Ofatumumab Versus Teriflunomide (P3.2-096)

Kappos, Ludwig; Bar-Or, Amit; Cohen, Jeffrey A.; Comi, Giancarlo; Correale, Jorge; Coyle, Patricia K.; Cross, Anne H.; de Seze, Jerome; Montalban, Xavier; Selmaj, Krzysztof; Wiendl, Heinz; Leppert, David; Kerloeguen, Cecile; Willi, Roman; Häring, Dieter A.; Tomic, Davorka; Goodyear, Alexandra; Merschhemke, Martin; Hauser, Stephen L. (Lippincott Williams & Wilkins, 2019-04-16)

Objective: To present the baseline characteristics of patients enrolled in the ASCLEPIOS I and II trials. Background: ASCLEPIOS I and II are two Phase 3 trials of identical design that are being conducted simultaneously ...
LB62 Ofatumumab vs Teriflunomide in Relapsing Multiple Sclerosis: Analysis of No Evidence of Disease Activity (NEDA-3) from ASCLEPIOS I and II Trials

Hauser, Stephen L.; Bar-Or, Amit; Cohen, Jeffrey A.; Comi, Giancarlo; Correale, Jorge; Coyle, Patricia K.; Cross, Anne H.; de Seze, Jerome; Montalban, Xavier; Selmaj, Krzysztof; Wiendl, Heinz; Willi, Roman; Li, Bingbing; Häring, Dieter A.; Ramnathan, Krishnan; Merschhemke, Martin; Kappos, Ludwig (Wiley, 2020-05-27)

Buscar en DSpace